SUMMARY We performed electrophysiologic studies before and after oral administration of disopyramide phosphate, 200 mg every 6 hours, in 20 patients with atrioventricular (AV) reentrant tachyeardia using a retrogradely conducting accessory pathway. Disopyramide markedly depressed retrograde accessory pathway conduction by increasing the mean ventricular paced cycle length that produced ventriculoatrial block (a2 287 4 to ¢ 392 22 msec, p < 0.01); it also depressed antegrade normal pathway AV conduction by increasing the atrial paced cycle length that produced AV block (287 9 to 328 7 msec, p < 0.01).
SUMMARY We performed electrophysiologic studies before and after oral administration of disopyramide phosphate, 200 mg every 6 hours, in 20 patients with atrioventricular (AV) reentrant tachyeardia using a retrogradely conducting accessory pathway. Disopyramide markedly depressed retrograde accessory pathway conduction by increasing the mean ventricular paced cycle length that produced ventriculoatrial block (a2 287 4 to ¢ 392 22 msec, p < 0.01); it also depressed antegrade normal pathway AV conduction by increasing the atrial paced cycle length that produced AV block (287 9 to 328 7 msec, p < 0.01).
In 14 patients, tachycardia could not be induced or sustained after disopyramide phosphate. In 13 patients, this reflected depression of the retrograde limb with either absence of atrial echoes (nine patients) or induction of nonsustained tachycardia that terminated after the QRS complex (four patients), and in one, it reflected depression of the antegrade limb with induction of a single atrial echo not followed by a QRS response. In six patients, sustained tachycardia could still be induced after disopyramide.
Oral disopyramide phosphate is effective in preventing induction of sustained AV reentrant tachyeardia in most patients. This effect is achieved primarily by depression of the retrograde limb of the reentrant circuit.
EFFECTIVE DRUG THERAPY for reentrant tachycardia in patients with the Wolff-Parkinson-White syndrome can be achieved by eliminating atrial or ventricular premature complexes responsible for induction of tachycardia, or by modifying the conduction properties of the reentrant circuit. l1 The former is difficult to achieve and hard to evaluate, while the latter can be evaluated with electrophysiologic studies in the catheterization laboratory. 3 6 Procainamide and quinidine increase the retrograde effective refractory period of the accessory pathway;2 3 5 digitalis,1 3 '3' proprano1o13 and verapamil4 8 " increase the antegrade effective refractory period of the atrioventricular (AV) node. These agents may prevent the induction or sustenance of tachycardia. The limited data available suggest that disopyramide increases refractoriness of the retrograde accessory pathway and can suppress reentrant tachycardia. [12] [13] [14] In this study, we evaluated the effects of oral disopyramide on induction and sustenance of AV reentrant tachycardia incorporating a retrogradely conducting accessory pathway in a large group of patients. These effects are examined in terms of the measurable properties of the components of the reentrant circuit.
Materials and Methods
The study group consisted of 20 patients, six females and 14 males, ages 17- ic documentation of recurrent paroxysmal supraventricular tachycardia, electrophysiologic demonstration of AV reentrant tachycardia incorporating a retrogradely conducting accessory pathway, and induction of sustained tachycardia necessitating termination with electrical stimulation on the day of control study. Patients 1-4 had ventricular preexcitation (three type A and one type B); patients 5 and 6 had intermittent ventricular preexcitation (type A, type B, respectively) and patients [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] had concealed accessory pathway (two right and 12 left) (table 1). Patient 6 had a leftsided concealed accessory pathway, and both the right and left accessory pathways were capable of retrograde conduction. Only the left-sided concealed accessory pathway could sustain tachycardia. The tachycardia incorporating the right accessory pathway always terminated spontaneously with a QRS complex not followed by an atrial response (retrograde block in the accessory pathway). Thus, the data on this patient's latter tachycardia are not presented.
Electrophysiologic Studies
After informed, written consent was obtained, electrophysiologic studies were performed with the patient supine and unsedated. All cardioactive drugs were discontinued at least 72 hours before the study. His bundle electrograms were recorded from the proximal two electrodes of a #7 quadripolar electrocatheter introduced percutaneously into the right femoral vein and placed across the tricuspid valve. The distal two electrodes were used for right ventricular pacing. A second #7 hexapolar electrocatheter was advanced to the coronary sinus through the right anitecubital vciin. In this position, the proximal four electrodes were agailist the lateral wall of right atrium near the junction of superior vena cava. The distal two electrodes were 454 used to record the left atrial electrogram from the coronary sinus, the middle two electrodes to record the high right atrial electrogram and the proximal two electrodes to stimulate the right atrium. Surface leads I, aVF and V1 were simultaneously recorded with the intracardiac electrograms on a multichannel oscilloscopic photographic recorder (Electronics for Medicine, VR-16) at paper speeds of 100, 150 and 250 mm/sec, using a filter setting of 30-500 Hz. Stimuli 2 msec long and approximately twice diastolic threshold were delivered by a programmable digital stimulator (Bloom and Associates).
The study protocol included (1) incremental atrial pacing up to the atrial paced cycle length that produced AV block; (2) atrial extrastimulus testing (A1A2 testing) at a driven cycle length of 500 msec, and double atrial extrastimulus testing (A1A2A3 testing) in patients in whom A1A2 testing failed to produce an echo beat or tachycardia; (3) incremental ventricular pacing up to the ventricular paced cycle length that produced ventriculoatrial (VA) block; and (4) ventricular extrastimulus testing (V1V2 testing) at a driven cycle length of 500 msec. AV reentrant tachycardia incorporating a retrogradely conducting accessory pathway was documented by an abnormal atrial activation sequence during induced tachycardia, an increase in VA interval or cycle length of tachycardia when bundle branch block occurred ipsilateral to the accessory pathway, and capture of the atrium by a ventricular extrastimulus during tachycardia when the His bundle was still refractory.3' 6, 15-9 At the end of the control study, the tip of the hexapolar electrocatheter was repositioned and secured at the right ventricular apex for subsequent electrophysiologic study; the quadripolar electrocatheter was removed. The patient was then given oral disopyramide phosphate, 200 mg every 6 hours, and the electrophysiologic studies were repeated 2 hours after the last dose 2-4 days after the control study. Three patients had mild urinary retention, but side effects necessitating discontinuation of disopyramide were not observed. Antegrade properties were evaluated by noting the longest atrial paced cycle length that produced seconddegree block in the accessory pathway or in the normal pathway, and by measuring the effective refractory period of the accessory pathway and the normal pathway. For comparison before and after disopyramide, antegrade properties were measured from the high right atrial electrograms. The antegrade effective refractory period of the accessory pathway is defined as the longest A,A2 at which A2 fails to conduct via the accessory pathway. The antegrade effective refractory period of the normal pathway (AV conducting system) is the longest A1A2 at which A2 fails to conduct via the normal pathway. The antegrade echo zone is defined as the zone of AA at which A2 provokes atrial echoes with or without tachycardia. The critical AV interval is defined as the shortest AV interval provoking AV reentrant atrial echoes or tachycardia. The maximal AV interval (MAV) is the longest AV interval achieved during incremental atrial pacing or extrastimulus testing.
Retrograde properties were evaluated by noting the longest ventricular paced cycle length that produced VA block and by measuring the effective refractory period of VA conduction. The retrograde effective refractory period of the accessory pathway is the longest VY2 interval at which V2 fails to conduct to the atria (in patients with relatively fixed VA interval), or the longest V1V2 at which V2 conducted to the atria with a sudden increase in V2A2 (in patients in whom the effective refractory period of the accessory pathway is longer than that of the normal pathway). The retrograde echo zone is defined as the zone of VIV2 at which V2 provokes AV reentrant ventricular echoes with or without tachycardia.
Sustained tachycardia is defined as an episode of induced AV reentrant tachycardia lasting longer than 2 minutes and requiring termination with electrical stimulation. Nonsustained tachycardia is defined as an induced episode of AV reentrant tachycardia that terminates spontaneously. The antegrade weak link of the reentrant circuit refers to termination of echoes or tachycardia occurring with an atrial response not followed by a ventricular response. The retrograde weak link of the reentrant circuit refers either to termination of echoes or tachycardia occurring with a ventricular response not followed by an atrial response, or to an AV interval longer than the observed control critical interval, without induction of AV reentrant atrial echoes or tachycardia.
Results Induction of Tachycardia Sustained AV reentrant tachycardia was induced in all 20 patients during the control study. In 14 patients, the tachycardia was induced by rapid atrial pacing (patients 3-7, 9, 10, 12, 13 and 15-19), in 16 In patients 11, 12, 13 and 20, only a single AV reentrant echo beat was induced. In patients 11, 12 and 13, the echo beat terminated with a QRS complex not followed by an atrial response, suggesting a retrograde weak link; in patient 20, the echo beat was terminated with an atrial response not followed by a QRS complex, suggesting an antegrade weak link.
In the remaining nine patients (patients 4, 5, 6 and 14-19), neither tachycardia nor a single echo beat was inducible ( fig. 2C ). In these nine patients, the maximal AV conduction time (maximal AV interval) during rapid atrial pacing or with atrial extrastimulus testing was longer than the critical AV interval during the control study, which suggests that refractoriness of the retrograde accessory pathway or atria is increased after disopyramide. disopyramide (NS) (fig. IC) The atrial paced cycle length that produced block in the normal pathway either remained the same (six patients) or lengthened ( 14 patients). Cycles lengths were 205-360 msec (mean 288 ± 9 msec) during the control study and 280-400 msec (mean 328 + 7 msec) after disopyramide (fig. 4) . The increase was statistically significant p < 0.01). The site of the antegrade block was proximal to the His bundle recording site in all the 20 patients before disopyramide. His bundle recording was not performed after disopyramide, so the exact site of block could not be ascertained after disopyramide. In each of the seven patients (cases 1-3 and 7-10) in whom tachycardia could be induced after disopyramide, the cycle length of tachycardia was longer than the cycle length that produced block in the normal pathway. In five of the remaining 13 patients in whom tachycardia could not be induced (cases 4, 5, 12, 16 and 19), the cycle length producing block in the normal pathway after disopyramide was shorter than the cycle length of tachycardia during the control 6, 11, 13, 14, 15, 17, 18 and 20) , the cycle length that produced block in the normal pathway was longer than the cycle length of tachycardia during the control study. The effective refractory period of the AV conducting system could be compared in only three patients before and after disopyramide; it was decreased in patients 7 and 7-10, in whom tachycardia could be induced after disopyramide, the cycle length of the tachycardia was longer than the ventricular paced cycle length that produced VA block (figs. IC and ID). In the only patient in whom nonsustained tachycardia could be induced after disopyramide (patient 3), the ventricular paced cycle length that produced VA block was identical to the cycle length of tachycardia. In the 13 patients with and without echo beat inducible after disopyramide, the ventricular paced cycle length that produced VA block was longer than the cycle length of tachycardia before disopyramide (cases 4-6 and 11-20) ( figs. 2A  and 2D) .
The retrograde effective refractory periods of the accessory pathway before and after disopyramide could be compared in 14 patients (cases 1-5, 8. 9, 1 1-13, 15, 16, 18 and 20) . The mean retrograde effective refractory period of the accessory pathway was < 266 ± 10 msec range (< 210 to < 320 msec) before disopyramide and increased to 330 ± 12 msec (range 230-390 msec) after disopyramide (p < 0.01). The retrograde echo zone could be defined in only two cases during the control study, but was lost in both after disopyramide (patients 2 and 1O). In patient 7, the retrograde echo zone was demonstrable only after disopyramide.
Discussion
Disopyramide phosphate has been used in the management of cardiac arrhythmias since the late 1960s.2W27 Microelectrophysiologic studies have shown that disopyramide decreases the rate of spontaneous phase-4 depolarization, decreases the upstroke slope of phase 0 and lengthens the action potential and the effective refractory period of His-Purkinje fibers.2" Macroelectrophysiologic studies of disopyramide in animals and man have shown that although its effect on the sinus node and AV node is insignificant, it lengthens His-Purkinje conduction and increases the refractory period of atria, the His-Purkinje system and the ventricles.29 36 Electrophysiologic studies in a limited number of patients with Wolff-Parkinson-White syndrome have shown that disopyramide prolongs both the conduction time and the refractory period of the accessory pathway in both antegrade and retrograde directions.)2-4 Disopyramide reportedly prevents sustenance of AV reentrant tachycardia and reduces the ventricular rate during atrial fibrillation.'2 Our findings in this study of oral disopyramide in 20 patients with AV reentrant tachycardia are consistent with those in previous studies of i.v. disopyramide. 12 13 Oral disopyramide lengthened the paced cycle length that produced block in the accessory pathway and increased the effective refractory period of the accessory pathway in both antegrade and retrograde directions. The effect of disopyramide on the antegrade normal pathway conduction was less consistent. However, disopyramide lengthens the atrial paced cycle length that produced block in the normal pathway in most patients. IN CLASSIC parasystole, an automatic focus is assumed to be totally independent of the electric activity elsewhere in the heart. Entrance block (a form of unidirectional block) is the barrier that protects the parasystolic center from exogenous influences. However, a mechanism by which nonparasystolic beats (NPBs) can modify the activity of a protected automatic center has been conceived by Jalife and Moe.
I They reasoned that "if an impulse cannot invade the pacemaker, but the pacemaker impulses can escape, then clearly there must be a viable ionic pathway across the blocked region." Using an in vitro preparation -the sucrose gap model -they established the existence of an electrotonic action exerted, by evoked action potentials or current pulses, on the activity of a protected pacemak- In this report, we present 12 patients with VP in whom the activity of the parasystolic center was predictably enhanced or depressed by the effect of NPBs, depending on their timing within the ectopic cycle. These cases are a clinical counterpart of the experimental findings and serve to delineate the diagnostic criteria of parasystolic modulation, underline the differences from the experimental results, and show the limitations of extrapolating the latter to the clinical situation.
Material and Methods
The ECGs of 50 patients with VP were carefully examined for the presence of ectopic cycle lengths that varied because of the presence of interposed NPBs, as described by Jalife and Moe.' Fifteen such patients (30%) were found, but two were excluded because the CIRCULATION
